Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
1.210
+0.030 (2.54%)
At close: Nov 26, 2025, 4:00 PM EST
1.200
-0.010 (-0.83%)
After-hours: Nov 26, 2025, 5:28 PM EST
Jupiter Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
41.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 233.28K | -404.76K | -63.44% |
| Dec 31, 2021 | 638.04K | -488.20K | -43.35% |
| Dec 31, 2020 | 1.13M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
JUNS News
- 4 weeks ago - Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing - GlobeNewsWire
- 3 months ago - Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador - GlobeNewsWire
- 4 months ago - Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science - GlobeNewsWire
- 4 months ago - Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 5 months ago - Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery - GlobeNewsWire
- 5 months ago - Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador - GlobeNewsWire
- 10 months ago - Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - GlobeNewsWire
- 10 months ago - Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial - GlobeNewsWire